-
C4 Therapeutics prices $182 million IPO
LONDON: RTW Venture Fund Limited notes the announcement by its portfolio company C4 Therapeutics on 01 October 2020 of its pricing of a $182.4 million initial public offering (IPO) and admission to trade on Nasdaq Global Market under the ticker “CCCC”. C4T is a US‐based biotech company pioneering a new class of small molecule…
-
Andrew Hirsch named Chief Executive Officer of C4 Therapeutics
WATERTOWN: C4 Therapeutics (C4T), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins through degradation, announced the hiring of Andrew Hirsch as the Company’s incoming chief executive officer. Mr. Hirsch comes to C4T from Agios Pharmaceuticals where he was chief financial officer and head of corporate development. Marc…
